Business Wire

Teckro Expands Its Leadership Position in Clinical Trials With New Hires Malia Lewin and Silvina Baudino to Scale Its Global Market Strategy

Share

Teckro, creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among study stakeholders, today announces two key hires: Malia Lewin as global head of strategy and Silvina Baudino to lead the Teckro site strategy. They are the latest experienced veterans to join Teckro’s leadership team.

Other notable hires since the start of the year, include:

  • Former Veeva Systems sales leaders Ciaran Avitabile and Jeremy Schwarz join as Teckro global head and US head of sales, respectively;
  • Previous Salesforce solution engineering leader Brian Sharkey joins to build Teckro’s global solution consulting function;
  • Cheryl Murphy, with 20+ years of experience in the pharmaceutical industry, joins as Teckro VP of customer engagement and delivery where she will lead operational excellence for a world-class customer experience.

Malia Lewin to Lead Teckro’s Strategy for Optimal Market and Product Fit

Malia Lewin has nearly 20 years of experience in the biopharma industry, serving in a variety of roles to champion new ideas, innovation and technological advancements in life sciences. Most recently, Malia was chief business officer at CherryCircle Software, a maker of cloud-based software for pharmaceutical manufacturing. Among her other roles, she served as global director of oncology strategy at Veeva Systems.

Malia says, “While clinical research pushes forward incredible scientific advancements, the management of clinical trial operations is woefully behind. This creates friction that needlessly impacts the time and cost of delivering new treatments. Teckro’s platform changes the game by allowing a seamless flow of vital information between sites and sponsors. This enables faster, safer, more efficient trials and an improved path for life-saving treatments to people around the world. ”

Silvina Baudino to Champion Teckro Requirements for Sites’ Needs

Also joining Teckro’s strategy team, Silvina Baudino brings more than 20 years of clinical trial industry experience, most recently as director of strategic site networks for IQVIA. Her career has encompassed a diverse range of responsibilities, including building and implementing innovative site-centric delivery models as well as creating strategies to improve quality and accessibility to clinical trials for patients globally.

“While public awareness and appreciation for clinical research improved with the pandemic, research site staff are struggling to work through backlogs of trials that were put on hold or delayed due to COVID-19,” Silvina explains. “Teckro is uniquely positioned to help site staff manage their demanding workloads to deliver the best outcomes for patients and preserve the quality of the research data.”

CEO Gary Hughes reflects on the current strength of Teckro, saying: “The depth of the expertise of our leadership team is testament to the belief in Teckro’s mission and our positive impact on clinical trials operations. This all-star team of leaders gives confidence to the rest of our staff, prospective employees, and our customers that we can continue to modernize and simplify clinical operations and accelerate the pace of clinical research.

Watch this short Q&A with Malia and Silvina to hear their thoughts on joining Teckro on International Clinical Trials Day and how they believe the future of clinical trials will evolve.

About Teckro

Teckro’s cloud-based clinical trial platform connects research sites, monitors and study teams with access to critical information, real-time decision support, and vital insights into clinical operations and trial performance. Teckro is used at more than 20,000 research sites and by thousands of investigators around the world. The company works with six out of the top 10 pharmaceutical companies as well as emerging biotechs. A number of trials run on Teckro are now starting to report success metrics in meeting endpoints, and others have been granted priority review by regulators in the US and Europe.

More Information:

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hannah Lippitt
hannah.lippitt@teckro.com
+44 7393334501

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by

illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release

illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont

Textron Aviation Broadens Aftermarket Connectivity Solutions for Cessna Citation Latitude by Offering Starlink High-Speed Internet18.9.2025 16:30:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Latitude following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918380069/en/ Textron Aviation broadens aftermarket connectivity solutions for Cessna Citation Latitude by offering Starlink high-speed internet (Photo Credit: Textron Aviation) “With Starlink connectivity now available as an upgrade, Citation Latitude customers can enjoy a seamless, high-speed in-flight experience that keeps them connected in more

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye